

Figure 6 Data flow and data capture in a toxicogenomic expert system.

and drug development in a cost- and time-efficient manner. In conjunction with reference databases, more informed decision-making could occur at early stages in the drug development process rather than after more costly animal or human trials Fig. 6.

REFERENCES

1. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98:503–517.
2. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 1990; 87:1663–1667.
3. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, Adams CL. Multiplexed biochemical assays with biological chips. Nature 1993; 364:555–556.
4. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet 1999; 21:20–24.
5. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray (see comments). Science 1995; 270:467–470.
6. Drmanac S, Kita D, Labat I, Hauser B, Schmidt C, Burczak JD, Drmanac R. Accurate sequencing by hybridization for DNA diagnostics and individual genomics. Nat Biotechnol 1998; 16:54–58.
7. Hacia JG. Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 1999; 21:42–47.